Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.
Company Details
- Employees
- 2
- Founded
- 2017
- Address
- 19900 Macarthur Blvd, Suite 550, Irvine,ca 92612,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- novustherapeutics.com
- Keywords
- Clinical Development, biotechnology, autoimmune diseases, transplant, ALS, Renal transplant, islet cell transplant, lupus nephritis, type 1 diabetes.
- HQ
- Irvine, Ca
Novus Therapeutics, Inc. Questions
Novus Therapeutics, Inc.'s website is novustherapeutics.com
Novus Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/novustherapeutics
Novus Therapeutics, Inc. has
2 employees.
View email and phone details for 2
employees at Novus Therapeutics, Inc..
Novus Therapeutics, Inc.'s industry is
Biotechnology Research
Novus Therapeutics, Inc.'s top competitors are
Travere Therapeutics,
Imbria Pharmaceuticals,
Onkure Therapeutics,
A2 Biotherapeutics, Inc.,
Ostic Pharma Pvt Ltd,
Climb Bio,
Adynxx, Inc,
Eledon Pharmaceuticals, Inc.,
Mediar Therapeutics,
Avanir Pharmaceuticals.
Novus Therapeutics, Inc.'s categories are Biotechnology Research
Novus Therapeutics, Inc.'s founding year is 2017
